Transcatheter intervention of modified Blalock-Taussig shunts in patients with hypoplastic left heart syndrome undergoing stage 1 palliation.

Background: While several studies have explored the outcomes of transcatheter interventions for modified Blalock-Taussig shunts (MBTSs) in a broad range of congenital heart diseases, none have specifically examined the interventions in patients with hypoplastic left heart syndrome (HLHS) who underwent Norwood palliation (NP). Methods: This retrospective study was conducted between 2020 and 2024, when 24 urgent interventions were performed on 17 patients at our center. We recorded several key outcomes, including early and late intervention-related complications, the need for reintervention, the interval between the NP and the first intervention, shunt patency following the intervention, associated morbidities, and thrombosis-related sudden events. Additionally, during follow-up, we documented the outcomes for patients who underwent the Glenn procedure and those who were palliated, including late death. Results: The median age and weight at the time of intervention were 88 days (range: 15-300 days) and 5 kg (range: 2.6-7.6 kg), respectively. The median interval between the Norwood procedure and the transcatheter intervention was 61 days (7-160 days), with median shunt patency lasting 62 days (1-150 days). Notably, there were no intervention-related complications or deaths. In-stent thrombosis, a late complication, occurred in four patients; two of these had impaired anticoagulation, including extracorporeal membrane oxygenation (ECMO)-related causes, while the other two, who were on aspirin, had multiple stents within the shunt, one of whom experienced sudden death. Six patients required seven reinterventions: four due to shunt obstruction or restenosis and two to delay surgery or provide palliation for patients unfit for surgery, aiding in pulmonary development. Conclusion: The transcatheter intervention of the MBTSs in patients with HLHS undergoing NP is considered both safe and potentially life-saving in emergent situations. This approach may facilitate improved pulmonary development, postpone the need for subsequent surgeries, and provide medium-term palliative care for critically ill patients. However, managing late complications such as stent thrombosis remains a significant challenge. Our findings indicate that risk factors for shunt thrombosis include using ECMO therapy, underlying coagulation disorders, impaired lymphatic drainage, requiring multiple stents within the shunt, and a prior history of thrombosis before intervention. Dual antiplatelet therapy is recommended to alleviate the risk of thrombotic events in this population.